Safety and Effectiveness of Unilateral MR-Guided Focused Ultrasound Thalamotomy for Essential Tremor

Launched by MEISHANSHAN · Jun 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment option for people with essential tremor (ET), a condition that causes uncontrollable shaking and can greatly affect daily life. The trial is looking at a noninvasive approach called Magnetic Resonance-guided Focused Ultrasound (MRgFUS), which targets a specific part of the brain to help reduce tremors. This method is being compared to standard medication treatments for patients who haven’t found relief from their tremors despite taking medicine.

To be eligible for the trial, participants need to be at least 22 years old, have a confirmed diagnosis of essential tremor, and experience significant difficulties in daily activities due to their tremors. Participants will be divided into two groups: one will receive the MRgFUS treatment, while the other will continue with their usual medication. Over the course of a year, researchers will monitor both groups to see how well the treatment works and how it impacts their quality of life. Participants should also expect regular follow-ups to assess their progress and any potential side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 22 years
• • Diagnosis of essential tremor confirmed by clinical criteria
• • Medication-refractory tremor with significant functional impairment
• • Ability to provide informed consent
• • Willingness to undergo follow-up assessments for 12 months
• Exclusion Criteria:
• • History of other neurological disorders (e.g., Parkinson's disease)
• • Presence of unstable medical conditions (e.g., uncontrolled hypertension)
• • Contraindications to MRI (e.g., implanted metal devices)
• • Severe cognitive impairment or psychiatric illness
• • Pregnancy or breastfeeding